{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T13:14:26Z","timestamp":1758633266989},"reference-count":115,"publisher":"Bentham Science Publishers Ltd.","issue":"1","license":[{"start":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T00:00:00Z","timestamp":1581552000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CHYR"],"published-print":{"date-parts":[[2020,2,13]]},"abstract":"<jats:sec><jats:title \/><jats:p>Management of arterial hypertension in patients with chronic kidney disease (CKD) remains a major challenge due to its high prevalence and associations with cardiovascular disease (CVD) and CKD progression. Several clinical trials and meta-analyses have demonstrated that aggressive treatment of hypertension in patients with and without CKD lowers the risk of CVD and all-cause mortality, nevertheless the effects of blood pressure (BP) lowering in terms of renal protection or harm remain controversial. Both home and ambulatory BP estimation have shown that patients with CKD display abnormal BP patterns outside of the office and further investigation is required, so as to compare the association of ambulatory versus office BP measurements with hard outcomes and adjust treatment strategies accordingly. Although renin-angiotensin system blockade appears to be beneficial in patients with advanced CKD, especially in the setting of proteinuria, discontinuation of renin-angiotensin system inhibition should be considered in the setting of frequent episodes of acute kidney injury or hypotension while awaiting the results of ongoing trials. In light of the new evidence in favor of renal denervation in arterial hypertension, the indications and benefits of its application in individuals with CKD need to be clarified by future studies. Moreover, the clinical utility of the novel players in the pathophysiology of arterial hypertension and CKD, such as microRNAs and the gut microbiota, either as markers of disease or as therapeutic targets, remains a subject of intensive research.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1573402115666190415153554","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T15:31:28Z","timestamp":1555428688000},"page":"45-54","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Hypertension in Chronic Kidney Disease: Novel Insights"],"prefix":"10.2174","volume":"16","author":[{"given":"Anila","family":"Duni","sequence":"first","affiliation":[{"name":"Department of Nephrology, School of Health Sciences, University of Ioannina, Ioannina, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelia","family":"Dounousi","sequence":"additional","affiliation":[{"name":"Department of Nephrology, School of Health Sciences, University of Ioannina, Ioannina, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paraskevi","family":"Pavlakou","sequence":"additional","affiliation":[{"name":"Department of Nephrology, School of Health Sciences, University of Ioannina, Ioannina, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodoros","family":"Eleftheriadis","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Medical School, University of Thessaly, Larissa, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vassilios","family":"Liakopoulos","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, 1st Department of Internal Medicine, AHEPA Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1053\/j.ajkd.2009.09.014","volume":"55","author":"Muntner P.","year":"2010","unstructured":"Muntner P.; Anderson A.; Charleston J.; Hypertension awareness, treatment, and control in adults with CKD: Results from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis 2010,55,441-451","journal-title":"Am J Kidney Dis"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.2215\/CJN.02130218","volume":"13","author":"Chang A.R.","year":"2018","unstructured":"Chang A.R.; Appel L.J.; Target blood pressure for cardiovascular disease prevention in patients with CKD. Clin J Am Soc Nephrol 2018,13(10),1572-1574","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.2215\/CJN.02010218","volume":"13","author":"Chang T.I.","year":"2018","unstructured":"Chang T.I.; Sarnak M.J.; Intensive blood pressure targets and kidney disease. Clin J Am Soc Nephrol 2018,13(10),1575-1577","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1053\/j.ackd.2015.01.003","volume":"22","author":"Sinha A.D.","year":"2015","unstructured":"Sinha A.D.; Agarwal R.; The complex relationship between CKD and ambulatory blood pressure patterns. Adv Chronic Kidney Dis 2015,22(2),102-107","journal-title":"Adv Chronic Kidney Dis"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","volume":"71","author":"Whelton P.K.","year":"2018","unstructured":"Whelton P.K.; Carey R.M.; Aronow W.S.; 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/ PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: Executive summary: A report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines. Hypertension 2018,71(6),1269-1324","journal-title":"Hypertension"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"373","author":"Wright J.T.","year":"2015","unstructured":"Wright J.T.; Williamson J.D.; Whelton P.K.; A randomized trial of intensive versus standard blood-pressure control. N Engl J Med SPRINT Research Group2015,373,2103-2116","journal-title":"N Engl J Med"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1161\/CIRCULATIONAHA.117.028441","volume":"136","author":"Soliman E.Z.","year":"2017","unstructured":"Soliman E.Z.; Ambrosius W.T.; Cushman W.C.; Effect of intensive blood pressure lowering on left ventricular hypertrophy in patients with hypertension: SPRINT (Systolic Blood Pressure Intervention Trial). Circulation SPRINT Research Study Group2017,136(5),440-450","journal-title":"Circulation"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2215\/CJN.06980615","volume":"11","author":"Paoletti E.","year":"2016","unstructured":"Paoletti E.; De Nicola L.; Gabbai F.B.; Associations of left ventricular hypertrophy and geometry with adverse outcomes in patients with CKD and hypertension. Clin J Am Soc Nephrol 2016,11(2),271-279","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1159\/000446122","volume":"43","author":"Papademetriou V.","year":"2016","unstructured":"Papademetriou V.; Zaheer M.; Doumas M.; Cardiovascular outcomes in action to control cardiovascular risk in diabetes: Impact of blood pressure level and presence of kidney disease. Am J Nephrol ACCORD Study Group2016,43,271-280","journal-title":"Am J Nephrol"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1001\/jamainternmed.2017.4377","volume":"177","author":"Malhotra R.","year":"2017","unstructured":"Malhotra R.; Nguyen H.A.; Benavente O.; Association between more intensive vs. less intensive blood pressure lowering and risk of mortality in chronic kidney disease stages 3 to 5: A systematic review and meta-analysis. JAMA Intern Med 2017,177(10),1498-1505","journal-title":"JAMA Intern Med"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"375","DOI":"10.7326\/M16-2966","volume":"167","author":"Beddhu S.","year":"2017","unstructured":"Beddhu S.; Rocco M.V.; Toto R.; Effects of intensive systolic blood pressure control on kidney and cardiovascular outcomes in persons without kidney disease: A secondary analysis of a randomized trial. Ann Intern Med SPRINT Research Group2017,167,375-383","journal-title":"Ann Intern Med"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1681\/ASN.2017020148","volume":"28","author":"Cheung A.K.","year":"2017","unstructured":"Cheung A.K.; Rahman M.; Reboussin D.M.; Effects of intensive BP control in CKD. J Am Soc Nephrol SPRINT Research Group2017,28,2812-2823","journal-title":"J Am Soc Nephrol"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1001\/jamainternmed.2017.0197","volume":"177","author":"Tsai W.C.","year":"2017","unstructured":"Tsai W.C.; Wu H.Y.; Peng Y.S.; Association of intensive blood pressure control and kidney disease progression in nondiabetic patients with chronic kidney disease: A systematic review and meta-analysis. JAMA Intern Med 2017,177(6),792-799","journal-title":"JAMA Intern Med"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S2213-8587(18)30099-8","volume":"6","author":"Beddhu S.","year":"2018","unstructured":"Beddhu S.; Greene T.; Boucher R.; Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials. Lancet Diabetes Endocrinol 2018,6(7),555-563","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1053\/j.ajkd.2017.08.021","volume":"71","author":"Rocco M.V.","year":"2018","unstructured":"Rocco M.V.; Sink K.M.; Lovato L.C.; Effects of intensive blood pressure treatment on acute kidney injury events in the Systolic Blood Pressure Intervention Trial (SPRINT). Am J Kidney Dis SPRINT Research Group2018,71(3),352-361","journal-title":"Am J Kidney Dis"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1681\/ASN.2017010040","volume":"28","author":"Ku E.","year":"2017","unstructured":"Ku E.; Bakris G.; Johansen K.L.; Acute Declines in Renal Function during Intensive BP Lowering: Implications for Future ESRD Risk. Am Soc Nephrol 2017,28(9),2794-2801","journal-title":"Am Soc Nephrol"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1681\/ASN.2018040365","volume":"29","author":"Ku E.","year":"2018","unstructured":"Ku E.; Ix J.H.; Jamerson K.; Acute declines in renal function during intensive BP lowering and long-term risk of death. J Am Soc Nephrol 2018,29(9),2401-2408","journal-title":"J Am Soc Nephrol"},{"key":"ref=18","first-page":"30879","volume":"pii: S0272-6386","author":"Malhotra R","year":"2018","unstructured":"Malhotra R; Craven T; Ambrosius WT; Effects of intensive blood pressure lowering on kidney tubule injury in CKD: A longitudinal subgroup analysis in SPRINT. Am J Kidney Dis SPRINT Research Group2018,pii: S0272-6386(18),30879-5","journal-title":"Am J Kidney Dis"},{"key":"ref=19","first-page":"30880","volume":"pii: S0272-6386","author":"Nadkarni GN","year":"2018","unstructured":"Nadkarni GN; Chauhan K; Rao V; Effect of intensive blood pressure lowering on kidney tubule injury: Findings from the ACCORD trial study participants. Am J Kidney Dis 2018,pii: S0272-6386(18),30880-1","journal-title":"Am J Kidney Dis"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"Williams B.","year":"2018","unstructured":"Williams B.; Mancia G.; Spiering W.; 2018 ESC\/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018,39,3021-3104","journal-title":"Eur Heart J"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S2213-8587(18)30134-7","volume":"6","author":"Mancia G.","year":"2018","unstructured":"Mancia G.; Target blood pressure and kidney protection. Lancet Diabetes Endocrinol 2018,6(7),521-523","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1093\/eurheartj\/ehu016","volume":"35","author":"Banegas J.R.","year":"2014","unstructured":"Banegas J.R.; Ruilope L.M.; de la Sierra A.; High prevalence of masked uncontrolled hypertension in people with treated hypertension. Eur Heart J 2014,35,3304-3312","journal-title":"Eur Heart J"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1712231","volume":"378","author":"Banegas J.R.","year":"2018","unstructured":"Banegas J.R.; Ruilope L.M.; de la Sierra A.; Relationship between clinic and ambulatory blood-pressure measurements and mortality. N Engl J Med 2018,378,1509-1520","journal-title":"N Engl J Med"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1161\/HYPERTENSIONAHA.116.08076","volume":"69","author":"Drawz P.E.","year":"2017","unstructured":"Drawz P.E.; Pajewski N.M.; Bates J.T.; Effect of intensive versus standard clinic-based hypertension management on ambulatory blood pressure: Results from the SPRINT (systolic blood pressure intervention trial) ambulatory blood pressure study. Hypertension 2017,69,42-50","journal-title":"Hypertension"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(18)30309-X","volume":"391","author":"McManus R.J.","year":"2018","unstructured":"McManus R.J.; Mant J.; Franssen M.; Efficacy of self-monitored blood pressure, with or without telemonitoring, for titration of antihypertensive medication (TASMINH4): An unmasked randomised controlled trial. Lancet TASMINH4 investigators2018,391(10124),949-959","journal-title":"Lancet"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"642","DOI":"10.2215\/CJN.08530815","volume":"11","author":"Drawz P.E.","year":"2016","unstructured":"Drawz P.E.; Alper A.B.; Anderson A.H.; Masked hypertension and elevated nighttime blood pressure in CKD: Prevalence and association with target organ damage. Clin J Am Soc Nephrol Chronic Renal Insufficiency Cohort Study Investigators2016,11,642-652","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/nep.12672","volume":"21","author":"Tang H.","year":"2016","unstructured":"Tang H.; Gong W.Y.; Zhang Q.Z.; Prevalence, determinants, and clinical significance of masked hypertension and white-coat hypertension in patients with chronic kidney disease. Nephrology (Carlton) 2016,21,841-850","journal-title":"Nephrology (Carlton)"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.2215\/CJN.12551117","volume":"13","author":"Thomas G.","year":"2018","unstructured":"Thomas G.; Drawz P.E.; BP measurement techniques: What they mean for patients with kidney disease. Clin J Am Soc Nephrol 2018,13(7),1124-1131","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ekir.2016.05.001","volume":"1","author":"Velasquez M.T.","year":"2016","unstructured":"Velasquez M.T.; Beddhu S.; Nobakht E.; Rahman M.; Raj D.S.; Ambulatory blood pressure in chronic kidney disease: Ready for prime time? Kidney Int Rep 2016,1(2),94-104","journal-title":"Kidney Int Rep"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1161\/HYPERTENSIONAHA.113.02110","volume":"63","author":"Salman I.M.","year":"2014","unstructured":"Salman I.M.; Hildreth C.M.; Ameer O.Z.; Phillips J.K.; Differential contribution of afferent and central pathways to the development of baroreflex dysfunction in chronic kidney disease. Hypertension 2014,63,804-810","journal-title":"Hypertension"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10157-014-0973-2","volume":"19","author":"Isobe S.","year":"2015","unstructured":"Isobe S.; Ohashi N.; Fujikura T.; Disturbed circadian rhythm of the intrarenal renin angiotensin system: Relevant to nocturnal hypertension and renal damage. Clin Exp Nephrol 2015,19,231-239","journal-title":"Clin Exp Nephrol"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1161\/HYPERTENSIONAHA.114.03533","volume":"64","author":"Dhaun N.","year":"2014","unstructured":"Dhaun N.; Moorhouse R.; MacIntyre I.M.; Diurnal variation in blood pressure and arterial stiffness in chronic kidney disease: The role of endothelin-1. Hypertension 2014,64,296-304","journal-title":"Hypertension"},{"key":"ref=33","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/9036450","volume":"2017","author":"Duni A.","year":"2017","unstructured":"Duni A.; Liakopoulos V.; Rapsomanikis K.P.; Dounousi E.; Chronic kidney disease and disproportionally increased cardiovascular damage: Does oxidative stress explain the burden? Oxid Med Cell Longev 2017,2017","journal-title":"Oxid Med Cell Longev"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1053\/j.ajkd.2014.06.014","volume":"64","author":"Minutolo R.","year":"2014","unstructured":"Minutolo R.; Gabbai F.B.; Agarwal R.; Assessment of achieved clinic and ambulatory blood pressure recordings and outcomes during treatment in hypertensive patients with CKD: A multicenter prospective cohort study. Am J Kidney Dis 2014,64,744-752","journal-title":"Am J Kidney Dis"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ijcard.2016.12.105","volume":"230","author":"Wang C.","year":"2017","unstructured":"Wang C.; Zhang J.; Li Y.; Masked hypertension, rather than white-coat hypertension, has a prognostic role in patients with non-dialysis chronic kidney disease. Int J Cardiol 2017,230,33-39","journal-title":"Int J Cardiol"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1253\/circj.CJ-17-0063","volume":"81","author":"Katafuchi E.","year":"2017","unstructured":"Katafuchi E.; Nakayama M.; Tanaka S.; Comparison of prognostic values of daytime and night-time systolic blood pressures on renal outcomes in patients with chronic kidney disease. Circ J 2017,81(10),1454-1462","journal-title":"Circ J"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1161\/HYPERTENSIONAHA.118.11608","volume":"72","author":"Scheppach J.B.","year":"2018","unstructured":"Scheppach J.B.; Raff U.; Toncar S.; Blood pressure pattern and target organ damage in patients with chronic kidney disease. Hypertension 2018,72(4),929-936","journal-title":"Hypertension"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2215\/CJN.06980615","volume":"11","author":"Paoletti E.","year":"2016","unstructured":"Paoletti E.; De Nicola L.; Gabbai F.B.; Associations of left ventricular hypertrophy and geometry with adverse outcomes in patientswith CKD and hypertension. Clin J Am Soc Nephrol 2016,11(2),271-279","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1681\/ASN.2012020145","volume":"23","author":"Park M.","year":"2012","unstructured":"Park M.; Hsu C.Y.; Li Y.; Associations between kidney function and subclinical cardiac abnormalities in CKD. J Am Soc Nephrol Chronic Renal Insufficiency Cohort (CRIC) Study Group2012,23(10),1725-1734","journal-title":"J Am Soc Nephrol"},{"key":"ref=40","volume":"10","author":"Ioannou K.","year":"2015","unstructured":"Ioannou K.; Stel V.S.; Dounousi E.; Inflammation, endothelial dysfunction and increased left ventricular mass in chronic kidney disease (CKD) patients: A longitudinal study. PLoS One 2015,10(9)","journal-title":"PLoS One"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1097\/HJH.0000000000001746","volume":"36","author":"Spoto B.","year":"2018","unstructured":"Spoto B.; Ntounousi E.; Testa A.; The sirtuin1 gene associates with left ventricular myocardial hypertrophy and remodeling in two chronic kidney disease cohorts: A longitudinal study. J Hypertens 2018,36(8),1705-1711","journal-title":"J Hypertens"},{"key":"ref=42","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/1507270","volume":"2016","author":"Dounousi E.","year":"2016","unstructured":"Dounousi E.; Bouba I.; Spoto B.; A genetic biomarker of oxidative stress, the paraoxonase 1 Q192R gene variant, associates with cardiomyopathy in CKD: A longitudinal study. Oxid Med Cell Longev 2016,2016","journal-title":"Oxid Med Cell Longev"},{"key":"ref=43","first-page":"iv136","volume":"28","author":"Stel V.S.","year":"2013","unstructured":"Stel V.S.; Ioannou K.; Br\u00fcck K.; Longitudinal association of body mass index and waist circumference with left ventricular mass in hypertensive predialysis chronic kidney disease patients. Nephrol Dial Transplant 2013,28(Suppl. 4),iv136-iv145","journal-title":"Nephrol Dial Transplant"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1016\/S0140-6736(16)31134-5","volume":"388","author":"Olsen M.H.","year":"2016","unstructured":"Olsen M.H.; Angell S.Y.; Asma S.; A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: The Lancet Commission on hypertension. Lancet 2016,388(10060),2665-2671","journal-title":"Lancet"},{"key":"ref=45","first-page":"1","volume":"133","author":"Nwankwo T.","year":"2013","unstructured":"Nwankwo T.; Yoon S.S.; Burt V.; Gu Q.; Hypertension among adults in the United States: National Health and Nutrition Examination Survey, 2011-2012. NCHS Data Brief 2013,133,1-8","journal-title":"NCHS Data Brief"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.atherosclerosis.2017.10.031","volume":"267","author":"Di Daniele N.","year":"2017","unstructured":"Di Daniele N.; Fegatelli D.A.; Rovella V.; Castagnola V.; Gabriele M.; Scuteri A.; Circadian blood pressure patterns and blood pressure control in patients with chronic kidney disease. Atherosclerosis 2017,267,139-145","journal-title":"Atherosclerosis"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1159\/000489749","volume":"43","author":"Kuczera P.","year":"2018","unstructured":"Kuczera P.; Kwiecie\u0144 K.; Adamczak M.; Relevance of peripheral, central or nighttime blood pressure measurements in the prediction of chronic kidney disease progression in patients with mild or no-proteinuria. Kidney Blood Press Res 2018,43(3),735-743","journal-title":"Kidney Blood Press Res"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.2215\/CJN.13181117","volume":"13","author":"Drawz P.E.","year":"2018","unstructured":"Drawz P.E.; Brown R.; De Nicola L.; Variations in 24-hour BP profiles in cohorts of patients with kidney disease around the world: The I-DARE study. Clin J Am Soc Nephrol CRIC Study Investigators2018,13(9),1348-1357","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1111\/j.1523-1755.2005.00527.x","volume":"68","author":"Tripepi G.","year":"2005","unstructured":"Tripepi G.; Fagugli R.M.; Dattolo P.; Prognostic value of 24-hour ambulatory blood pressure monitoring and of night\/ day ratio in nondiabetic, cardiovascular events-free hemodialysis patients. Kidney Int 2005,68,1294-1302","journal-title":"Kidney Int"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jash.2015.04.001","volume":"9","author":"Lee M.H.","year":"2015","unstructured":"Lee M.H.; Ko K.M.; Ahn S.W.; The impact of kidney transplantation on 24-hour ambulatory blood pressure in end-stage renal disease patients. J Am Soc Hypertens 2015,9,427-434","journal-title":"J Am Soc Hypertens"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/HJH.0000000000001530","volume":"36","author":"Mallamaci F.","year":"2018","unstructured":"Mallamaci F.; D\u2019Arrigo G.; Tripepi R.; Office, standardized and 24-h ambulatory blood pressure and renal function loss in renal transplant patients. J Hypertens 2018,36(1),119-125","journal-title":"J Hypertens"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2215\/CJN.08620817","volume":"13","author":"Rahman M.","year":"2018","unstructured":"Rahman M.; Hsu J.Y.; Desai N.; Central blood pressure and cardiovascular outcomes in chronic kidney disease. Clin J Am Soc Nephrol CRIC Study Investigators2018,13(4),585-595","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1161\/HYPERTENSIONAHA.117.09855","volume":"70","author":"Sood M.M.","year":"2017","unstructured":"Sood M.M.; Akbari A.; Manuel D.G.; Longitudinal blood pressure in late-stage chronic kidney disease and the risk of end-stage kidney disease or mortality (best blood pressure in chronic kidney disease study). Hypertension 2017,70(6),1210-1218","journal-title":"Hypertension"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.kint.2017.04.030","volume":"92","author":"Navaneethan S.D.","year":"2017","unstructured":"Navaneethan S.D.; Schold J.D.; Jolly S.E.; Blood pressure parameters are associated with all-cause and cause-specific mortality in chronic kidney disease. Kidney Int 2017,92(5),1272-1281","journal-title":"Kidney Int"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1681\/ASN.2016111186","volume":"28","author":"Hermida R.C.","year":"2017","unstructured":"Hermida R.C.; Ayala D.E.; Moj\u00f3n A.; Fern\u00e1ndez J.R.; sleep-time ambulatory BP is an independent prognostic marker of CKD. J Am Soc Nephrol 2017,28(9),2802-2811","journal-title":"J Am Soc Nephrol"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/kisup.2013.79","volume":"3","author":"Kazancioglu R.","year":"2013","unstructured":"Kazancioglu R.; Risk factors for chronic kidney disease: An update. Kidney Int Suppl 2013,3(4),368-371","journal-title":"Kidney Int Suppl"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1177\/014107680209500804","volume":"95","author":"Devonald M.A.J.","year":"2002","unstructured":"Devonald M.A.J.; Karet F.E.; Targeting the renin angiotensin system in patients with renal disease. J R Soc Med 2002,95(8),391-397","journal-title":"J R Soc Med"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1681\/ASN.2004110968","volume":"16","author":"Chiurchiu C.","year":"2005","unstructured":"Chiurchiu C.; Remuzzi G.; Ruggenenti P.; Angiotensin converting enzyme inhibition and renal protection in nondiabetic patients: the data of the meta-analyses. J Am Soc Nephrol 2005,16(Suppl. 1),S58-S63","journal-title":"J Am Soc Nephrol"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jash.2018.01.005","volume":"12","author":"Der Mesropian P.J.","year":"2018","unstructured":"Der Mesropian P.J.; Shaikh G.; Cordero Torres E.; Bilal A.; Mathew R.O.; Antihypertensive therapy in nondiabetic chronic kidney disease: A review and update. Am Soc Hypertens 2018,12(3),154-181","journal-title":"Am Soc Hypertens"},{"key":"ref=60","first-page":"30796","volume":"pii: S0272-6386","author":"Weir MR","year":"2018","unstructured":"Weir MR; Lakkis JI; Jaar B; Use of renin-angiotensin system blockade in advanced CKD: An NKF-KDOQI controversies report. Am J Kidney Dis 2018,pii: S0272-6386(18),30796-0","journal-title":"Am J Kidney Dis"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1001\/jamainternmed.2013.12700","volume":"174","author":"Hsu T.W.","year":"2014","unstructured":"Hsu T.W.; Liu J.S.; Hung S.C.; Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with advanced chronic kidney disease, hypertension, and anemia. JAMA Intern Med 2014,174(3),347-354","journal-title":"JAMA Intern Med"},{"key":"ref=62","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1159\/000441684","volume":"42","author":"Jovanovich A.J.","year":"2015","unstructured":"Jovanovich A.J.; Chonchol M.B.; Sobhi A.; Mineral metabolites, II inhibition and outcomes in advanced chronic kidney disease. Am J Nephrol 2015,42(5),361-368","journal-title":"Am J Nephrol"},{"key":"ref=63","volume":"12","author":"Oh Y.J.","year":"2017","unstructured":"Oh Y.J.; Kim S.M.; Shin B.C.; The impact of renin-angiotensin system blockade on renal outcomes and mortality in predialysis patients with advanced chronic kidney disease. PLoS One 2017,12(1)","journal-title":"PLoS One"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/ndt\/gfw166.13","volume":"31","author":"Bhandari S.","year":"2016","unstructured":"Bhandari S.; Ives N.; Brettell E.A.; Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor\/ angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial. Nephrol Dial Transplant 2016,31(2),255-261","journal-title":"Nephrol Dial Transplant"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1093\/ndt\/gfp511","volume":"25","author":"Ahmed A.K.","year":"2010","unstructured":"Ahmed A.K.; Kamath N.S.; El Kossi M.; El Nahas A.M.; The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. Nephrol Dial Transplant 2010,25(12),3977-3982","journal-title":"Nephrol Dial Transplant"},{"key":"ref=66","doi-asserted-by":"crossref","first-page":"c63","DOI":"10.1159\/000228536","volume":"113","author":"Onuigbo M.A.","year":"2009","unstructured":"Onuigbo M.A.; Analytical review of the evidence for renoprotection by renin-angiotensin-aldosterone system blockade in chronic kidney disease - a call for caution. Nephron Clin Pract 2009,113(2),c63-c69","journal-title":"Nephron Clin Pract"},{"key":"ref=67","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/sj.ki.5001684","volume":"70","author":"Hamming I.","year":"2006","unstructured":"Hamming I.; van Goor H.; Navis G.J.; ACE inhibitor use and the increased long-term risk of renal failure in diabetes. [letter] Kidney Int author reply 1378. 2006,70(7),1377-1378","journal-title":"Kidney Int"},{"key":"ref=68","volume":"7","author":"Ku E.","year":"2018","unstructured":"Ku E.; McCulloch C.E.; Vittinghoff E.; Lin F.; Use of antihypertensive agents and association with risk of adverse outcomes in chronic kidney disease: focus on angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. J Am Heart Assoc 2018,7(19)","journal-title":"J Am Heart Assoc"},{"key":"ref=69","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2174\/1570161115666170201113817","volume":"15","author":"Georgianos P.I.","year":"2017","unstructured":"Georgianos P.I.; Vaios V.; Eleftheriadis T.; Zebekakis P.; Liakopoulos V.; Mineralocorticoid antagonists in ESRD: An overview of clinical trial evidence. Curr Vasc Pharmacol 2017,15(6),599-606","journal-title":"Curr Vasc Pharmacol"},{"key":"ref=70","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000492622","volume":"48","author":"Agarwal R.","year":"2018","unstructured":"Agarwal R.; Garza D.; Mayo M.R.; Patiromer to enable spironolactone use in the treatment of patients with resistant hypertension and chronic kidney disease: Rationale and design of the AMBER study. Am J Nephrol 2018,48(3),172-180","journal-title":"Am J Nephrol"},{"key":"ref=71","doi-asserted-by":"crossref","first-page":"R79","DOI":"10.1152\/ajpregu.00351.2014","volume":"308","author":"Kopp U.C.","year":"2015","unstructured":"Kopp U.C.; Role of renal sensory nerves in physiological and pathophysiological conditions. Am J Physiol Regul Comp Physiol 2015,308,R79-R95","journal-title":"Am J Physiol Regul Comp Physiol"},{"key":"ref=72","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1161\/HYPERTENSIONAHA.110.163014","volume":"57","year":"2011","unstructured":"Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension Symplicity HTN-1 Investigators2011,57,911-917","journal-title":"Hypertension"},{"key":"ref=73","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(10)62039-9","volume":"376","year":"2010","unstructured":"Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, B\u00f6hm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): A randomised controlled trial. Lancet Symplicity HTN-2 Investigators2010,376,1903-1909","journal-title":"Lancet"},{"key":"ref=74","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJMoa1402670","volume":"370","author":"Bhatt D.L.","year":"2014","unstructured":"Bhatt D.L.; Kandzari D.E.; O\u2019Neill W.W.; A controlled trial of renal denervation for resistant hypertension. N Engl J Med SYMPLICITY HTN-3 Investigators2014,370,1393-1401","journal-title":"N Engl J Med"},{"key":"ref=75","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/S0140-6736(17)32281-X","volume":"390","author":"Townsend R.R.","year":"2017","unstructured":"Townsend R.R.; Mahfoud F.; Kandzari D.E.; SPYRAL HTN-OFF MED trial investigators. Catheter- based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN- OFF MED): A randomised, sham-controlled, proof-of-concept trial. Lancet 2017,390,2160-2170","journal-title":"Lancet"},{"key":"ref=76","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1016\/S0140-6736(18)30951-6","volume":"391","author":"Kandzari D.E.","year":"2018","unstructured":"Kandzari D.E.; B\u00f6hm M.; Mahfoud F.; Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN- ON MED proof- of-concept randomized trial. Lancet SPYRAL HTN-ON MED Trial Investigators2018,391,2346-2355","journal-title":"Lancet"},{"key":"ref=77","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1016\/S0140-6736(18)31082-1","volume":"391","author":"Azizi M.","year":"2018","unstructured":"Azizi M.; Schmieder R.E.; Mahfoud F.; RADIANCE-HTN Investigators. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE- HTN SOLO): A multicentre, international, single- blind, randomised, sham- controlled trial. Lancet 2018,391,2335-2345","journal-title":"Lancet"},{"key":"ref=78","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.kint.2018.08.002","volume":"94","author":"Wyatt C.M.","year":"2018","unstructured":"Wyatt C.M.; Textor S.C.; Emerging evidence on renal denervation for the treatment of hypertension. Kidney Int 2018,94(4),644-646","journal-title":"Kidney Int"},{"key":"ref=79","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3389\/fendo.2013.00161","volume":"4","author":"Aroor A.R.","year":"2013","unstructured":"Aroor A.R.; Demarco V.G.; Jia G.; The role of tissue Renin - Angiotensin - aldosterone system in the development of endothelial dysfunction and arterial stiffness. Front Endocrinol 2013,4,161","journal-title":"Front Endocrinol"},{"key":"ref=80","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1161\/CIRCRESAHA.114.302524","volume":"114","author":"Mancia G.","year":"2014","unstructured":"Mancia G.; Grassi G.; The autonomic nervous system and hypertension. Circ Res 2014,114,1804-1814","journal-title":"Circ Res"},{"key":"ref=81","first-page":"130","volume":"125","author":"Harrison D.G.","year":"2014","unstructured":"Harrison D.G.; The immune system in hypertension. Trans Am Clin Climatol Assoc 2014,125,130-140","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"ref=82","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.2174\/092986711795496827","volume":"18","author":"Liakopoulos V.","year":"2011","unstructured":"Liakopoulos V.; Georgianos P.I.; Eleftheriadis T.; Sarafidis P.A.; Epigenetic mechanisms and kidney diseases. Curr Med Chem 2011,18(12),1733-1739","journal-title":"Curr Med Chem"},{"key":"ref=83","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrneph.2014.202","volume":"11","author":"Trionfini P.","year":"2015","unstructured":"Trionfini P.; Benigni A.; Remuzzi G.; MicroRNAs in kidney physiology and disease. Nat Rev Nephrol 2015,11(1),23","journal-title":"Nat Rev Nephrol"},{"key":"ref=84","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.kint.2018.06.033","volume":"94","author":"Brandenburger T.","year":"2018","unstructured":"Brandenburger T.; Salgado Somoza A.; Devaux Y.; Lorenzen J.M.; Noncoding RNAs in acute kidney injury. Kidney Int 2018,94(5),870-881","journal-title":"Kidney Int"},{"key":"ref=85","doi-asserted-by":"crossref","first-page":"F793","DOI":"10.1152\/ajprenal.00273.2011","volume":"301","author":"Zarjou A.","year":"2011","unstructured":"Zarjou A.; Yang S.; Abraham E.; Agarwal A.; Liu G.; Identification of a microRNA signature in renal fibrosis: Role of miR-21. Am J Physiol Renal Physiol 2011,301,F793-F801","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref=86","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1681\/ASN.2010111168","volume":"22","author":"Zhong X.","year":"2011","unstructured":"Zhong X.; Chung A.C.; Chen H.Y.; Meng X.M.; Lan H.Y.; Smad3- mediated upregulation of miR-21 promotes renal fibrosis. J Am Soc Nephrol 2011,22,1668-1681","journal-title":"J Am Soc Nephrol"},{"key":"ref=87","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41440-018-0071-z","volume":"41","author":"Li X.","year":"2018","unstructured":"Li X.; Wei Y.; Wang Z.; microRNA-21 and hypertension. Hypertens Res 2018,41(9),649-661","journal-title":"Hypertens Res"},{"key":"ref=88","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/jch.12900","volume":"19","author":"Parthenakis F.","year":"2017","unstructured":"Parthenakis F.; Marketou M.; Kontaraki J.; Low levels of microRNA-21 are a marker of reduced arterial stiffness in well-controlled hypertension. J Clin Hypertens (Greenwich) 2017,19,235-240","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref=89","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/978-3-319-22671-2_11","volume":"888","author":"Marques F.Z.","year":"2015","unstructured":"Marques F.Z.; Charchar F.J.; MicroRNAs in essential hypertension and blood pressure regulation. Adv Exp Med Biol 2015,888,215-235","journal-title":"Adv Exp Med Biol"},{"key":"ref=90","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.yjmcc.2014.06.008","volume":"75","author":"Kemp J.R.","year":"2014","unstructured":"Kemp J.R.; Unal H.; Desnoyer R.; Yue H.; Bhatnagar A.; Karnik S.S.; Angiotensin II-regulated microRNA 483-3p directly targets multiple components of the renin-angiotensin system. J Mol Cell Cardiol 2014,75,25-39","journal-title":"J Mol Cell Cardiol"},{"key":"ref=91","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1161\/HYPERTENSIONAHA.111.180729","volume":"58","author":"Marques F.Z.","year":"2011","unstructured":"Marques F.Z.; Campain A.E.; Tomaszewski M.; Gene expression profiling reveals renin mRNA overexpression in human hypertensive kidneys and a role for microRNAs. Hypertension 2011,58,1093-1098","journal-title":"Hypertension"},{"key":"ref=92","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1210\/en.2007-1686","volume":"149","author":"Romero D.G.","year":"2008","unstructured":"Romero D.G.; Plonczynski M.W.; Carvajal C.A.; Gomez-Sanchez E.P.; Gomez-Sanchez C.E.; Microribonucleic acid-21 increases aldosterone secretion and proliferation in H295R human adrenocortical cells. Endocrinology 2008,149,2477-2483","journal-title":"Endocrinology"},{"key":"ref=93","doi-asserted-by":"crossref","first-page":"927","DOI":"10.3390\/ijms19040927","volume":"19","author":"Leimena C.","year":"2018","unstructured":"Leimena C.; Qiu H.; Non-coding RNA in the pathogenesis, progression and treatment of hypertension. Int J Mol Sci 2018,19(4),927","journal-title":"Int J Mol Sci"},{"key":"ref=94","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1161\/CIRCRESAHA.115.303970","volume":"116","author":"Zhao N.","year":"2015","unstructured":"Zhao N.; Koenig S.N.; Trask A.J.; Mir145 regulates TGFBR2 expression and matrix synthesis in vascular smooth muscle cells. Circ Res 2015,116,23-34","journal-title":"Circ Res"},{"key":"ref=95","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1161\/HYPERTENSIONAHA.112.197301","volume":"60","author":"Sun H.X.","year":"2012","unstructured":"Sun H.X.; Zeng D.Y.; Li R.T.; Essential role of microRNA-155 in regulating endothelium-dependent vasorelaxation by targeting endothelial nitric oxide synthase. Hypertension 2012,60,1407-1414","journal-title":"Hypertension"},{"key":"ref=96","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.3892\/ijmm.2015.2181","volume":"35","author":"Zhang J.","year":"2015","unstructured":"Zhang J.; Zhao F.; Yu X.; Lu X.; Zheng G.; MicroRNA- 155 modulates the proliferation of vascular smooth muscle cells by targeting endothelial nitric oxide synthase. Int J Mol Med 2015,35,1708-1714","journal-title":"Int J Mol Med"},{"key":"ref=97","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1073\/pnas.0610731104","volume":"104","author":"O\u2019Connell R.M.","year":"2007","unstructured":"O\u2019Connell R.M.; Taganov K.D.; Boldin M.P.; Cheng G.; Baltimore D.; MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci USA 2007,104,1604-1609","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=98","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1093\/ndt\/gfr485","volume":"26","author":"Neal C.S.","year":"2011","unstructured":"Neal C.S.; Michael M.Z.; Pimlott L.K.; Yong T.Y.; Li J.Y.; Gleadle J.M.; Circulating microRNA expression is reduced in chronic kidney disease. Nephrol Dial Transplant 2011,26,3794-3802","journal-title":"Nephrol Dial Transplant"},{"key":"ref=99","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.jash.2017.10.008","volume":"11","author":"Klimczak D.","year":"2017","unstructured":"Klimczak D.; Kuch M.; Pilecki T.; \u017bochowska D.; Wirkowska A.; P\u0105czek L.; Plasma microRNA-155-5p is increased among patients with chronic kidney disease and nocturnal hypertension. J Am Soc Hypertens 2017,11(12),831-841","journal-title":"J Am Soc Hypertens"},{"key":"ref=100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0176734","volume":"12","author":"Nandakumar P.","year":"2017","unstructured":"Nandakumar P.; Tin A.; Grove M.L.; MicroRNAs in the miR-17 and miR-15 families are downregulated in chronic kidney disease with hypertension. PLoS One 2017,12","journal-title":"PLoS One"},{"key":"ref=101","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/imm.12231","volume":"142","author":"McDermott A.J.","year":"2014","unstructured":"McDermott A.J.; Huffnagle G.B.; The microbiome and regulation of mucosal immunity. Immunology 2014,142,24-31","journal-title":"Immunology"},{"key":"ref=102","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1161\/HYPERTENSIONAHA.115.05315","volume":"65","author":"Yang T.","year":"2015","unstructured":"Yang T.; Santisteban M.M.; Rodriguez V.; Gut dysbiosis is linked to hypertension. Hypertension 2015,65,1331-1340","journal-title":"Hypertension"},{"key":"ref=103","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1152\/physiolgenomics.00136.2014","volume":"47","author":"Mell B.","year":"2015","unstructured":"Mell B.; Jala V.R.; Mathew A.V.; Evidence for a link between gut microbiota and hypertension in the Dahl rat. Physiol Genomics 2015,47,187-197","journal-title":"Physiol Genomics"},{"key":"ref=104","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40168-016-0222-x","volume":"5","author":"Li J.","year":"2017","unstructured":"Li J.; Zhao F.; Wang Y.; Gut microbiota dysbiosis contributes to the development of hypertension. Microbiome 2017,5(1),14","journal-title":"Microbiome"},{"key":"ref=105","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nature24628","volume":"551","author":"Wilck N.","year":"2017","unstructured":"Wilck N.; Matus M.G.; Kearney S.M.; Salt- responsive gut commensal modulates T17 axis and disease. Nature 2017,551,585-589","journal-title":"Nature"},{"key":"ref=106","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/ki.2012.345","volume":"83","author":"Vaziri N.D.","year":"2013","unstructured":"Vaziri N.D.; Wong J.; Pahl M.; Chronic kidney disease alters intestinal microbial flora. Kidney Int 2013,83,308-315","journal-title":"Kidney Int"},{"key":"ref=107","doi-asserted-by":"crossref","DOI":"10.1038\/cti.2016.36","volume":"5","author":"Felizardo R.J.","year":"2016","unstructured":"Felizardo R.J.; Castoldi A.; Andrade- Oliveira V, C\u00e2mara NO. The microbiota and chronic kidney diseases: A double- edged sword. Clin Transl Immunology 2016,5(6)","journal-title":"Clin Transl Immunology"},{"key":"ref=108","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1185\/03007990903069249","volume":"25","author":"Ranganathan N.","year":"2009","unstructured":"Ranganathan N.; Friedman E.A.; Tam P.; Rao V.; Ranganathan P.; Dheer R.; Probiotic dietary supplementation in patients with stage 3 and 4 chronic kidney disease: A 6-month pilot scale trial in Canada. Curr Med Res Opin 2009,25,1919-1930","journal-title":"Curr Med Res Opin"},{"key":"ref=109","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s101570200016","volume":"6","author":"Fukuuchi F.","year":"2002","unstructured":"Fukuuchi F.; Hida M.; Aiba Y.; Intestinal bacteria- derived putrefactants in chronic renal failure. Clin Exp Nephrol 2002,6,99-104","journal-title":"Clin Exp Nephrol"},{"key":"ref=110","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/MNH.0b013e328358c8d5","volume":"21","author":"Vaziri N.D.","year":"2012","unstructured":"Vaziri N.D.; CKD impairs barrier function and alters microbial flora of the intestine: A major link to inflammation and uremic toxicity. Curr Opin Nephrol Hypertens 2012,21(6),587-592","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"ref=111","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1440-1797.2012.01647.x","volume":"17","author":"Wang F.","year":"2012","unstructured":"Wang F.; Jiang H.; Shi K.; Ren Y.; Zhang P.; Cheng S.; Gut bacterial translocation is associated with microinflammation in end- stage renal disease patients. Nephrology 2012,17,733-738","journal-title":"Nephrology"},{"key":"ref=112","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000450619","volume":"135","author":"Kikuchi M.","year":"2017","unstructured":"Kikuchi M.; Ueno M.; Itoh Y.; Suda W.; Hattori M.; Uremic toxin- producing gut microbiota in rats with chronic kidney disease. Nephron 2017,135,51-60","journal-title":"Nephron"},{"key":"ref=113","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/s41598-017-01387-y","volume":"7","author":"Xu K.Y.","year":"2017","unstructured":"Xu K.Y.; Xia G.H.; Lu J.Q.; Impaired renal function and dysbiosis of gut microbiota contribute to increased trimethylamine- N-oxide in chronic kidney disease patients. Sci Rep 2017,7,1445","journal-title":"Sci Rep"},{"key":"ref=114","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000355788","volume":"39","author":"Zoccali C.","year":"2014","unstructured":"Zoccali C.; Tripepi G.; Dounousi E.; Mallamaci F.; Chronic kidney disease (CKD) as a systemic disease: whole body autoregulation and inter-organcross-talk. Kidney Blood Press Res 2014,39(2-3),134-141","journal-title":"Kidney Blood Press Res"},{"key":"ref=115","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41581-018-0018-2","volume":"14","author":"Yang T.","year":"2018","unstructured":"Yang T.; Richards E.M.; Pepine C.J.; Raizada M.K.; The gut microbiota and the brain-gut-kidney axis in hypertension and chronic kidney disease. Nat Rev Nephrol 2018,14(7),442-456","journal-title":"Nat Rev Nephrol"}],"container-title":["Current Hypertension Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/171629","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,6]],"date-time":"2020-12-06T14:18:50Z","timestamp":1607264330000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/171629\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,13]]},"references-count":115,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2,13]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573402115666190415153554","relation":{},"ISSN":["1573-4021"],"issn-type":[{"value":"1573-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2,13]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-03-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-31","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}